PPA Exposure Misclassification Bias Prevented, HSP Researchers Maintain
This article was originally published in The Tan Sheet
Executive Summary
Hemorrhagic Stroke Project procedures to measure participant recall and product classification prevented misclassification bias related to case and control subjects' phenylpropanolamine (PPA) exposure, Yale University researchers assert.
You may also be interested in...
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.
PPA Literature Relevance To Ephedra Supplement Safety Questioned
Structural and pharmacological differences between phenylpropanolamine and other ephedrine alkaloids negate FDA's heavy reliance on PPA literature in its analysis of adverse health effects caused by dietary supplements, industry consultants asserted at an Aug. 8-9 Public Health Service meeting in Washington, D.C.
PPA Increases Hemorrhagic Stroke Risk - Yale Study
The use of OTC cough/cold remedies or appetite suppressants containing phenylpropanolamine (PPA) increases the odds of hemorrhagic stroke by a factor of 1.49, according to a paper entitled "Phenylpropanolamine & Risk of Hemorrhagic Stroke: Final Report of the Hemorrhagic Stroke Project," released by Yale University May 10.